The Food and Drug Administration is reviewing a first-of-its-kindapplication from HRA Pharma for Opill. If green-lit by the agency, Opillwould become the first daily, hormonal birth control pill sold without aprescription. The submission of the application follows more than sixyears of studies the company has run. Alice Miranda Ollstein reports.